Bladder Cancer

Siamak Daneshmand, MD, associate professor of Urology, Director of Clinical Research, Keck School of Medicine of USC, discusses blue light cystoscopy compared with white light cystoscopy for patients with bladder cancer.

When epacadostat, an IDO1 inhibitor, was combined with pembrolizumab (Keytruda), a PD-1 inhibitor, responses were seen in 35% of patients with advanced urothelial carcinoma, according to findings presented during the 2017 ASCO Annual Meeting.  

It’s been a busy month at the FDA. Here’s a look back at all the news in the oncology field to come out of the FDA during the month of May.

The addition of ramucirumab to docetaxel led to a statistically significant improvement in progression-free survival versus docetaxel alone in previously treated patients with locally advanced or unresectable or metastatic urothelial carcinoma.

Edward Messing, MD, discusses his paper which found patients who underwent chemotherapy following transurethral resection of bladder tumor were less likely to have tumor recurrence.

Arjun V. Balar, MD, discusses the impact of the approval of pembrolizumab and other immunotherapy agents in urothelial carcinoma, as well as the next steps with these treatments.

Peter Black, MD, discusses the recent explosion of FDA approvals in the field of urothelial carcinoma, including durvalumab.

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer.

Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discussed results of the KEYNOTE-052 study of pembrolizumab as a first-line therapy for patients with cisplatin-ineligible advanced urothelial cancer.

Jay D. Raman, MD, professor of Surgery and chief of the Division of Urology at Penn State Milton S. Hershey Medical Center, discusses hematuria in patients with urothelial carcinoma.

Pembrolizumab (Keytruda) has been approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Based on results from Maslach Burnout Inventory (MBI) questions included as part of the 2016 American Urological Association (AUA) Census, burnout rates among urologists are lower than previously reported, but the issue still remains important.

Pam Profusek, RN, MS, discusses how to manage the AEs associated with immunotherapy agents, like durvalumab.

Atezolizumab failed to meet the primary endpoint of improving overall survival in the second-line setting for patients with locally advanced or metastatic urothelial carcinoma.

An accelerated approval for the PD-L1 inhibitor avelumab (Bavencio) has been granted by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Matthew I. Milowsky, MD, discusses advances with checkpoint inhibitors in the treatment paradigm for urothelial cancer.

An overview of FDA news that happened in April.

The PD-L1 inhibitor durvalumab has been granted an accelerated approval by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Emil Christensen, PhD candidate, Aarhus University Hospital, Denmark, discusses a liquid biopsy analysis of <em>FGFR3</em> and <em>PIK3CA</em> hotspot mutations for disease surveillance in bladder cancer.

Atezolizumab (Tecentriq) has been granted an accelerated approval by the FDA as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

The IDO1 inhibitor BMS-986205 had &quot;best-in-class&quot; activity as demonstrated by kynurenine reductions and IDO1 inhibition for patients with advanced tumors in a phase I/IIa study.

Evan Y. Yu, MD, discusses&nbsp;the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.

The PD-L1 inhibitor durvalumab demonstrated compelling clinical activity and a manageable safety profile as second-line therapy for locally advanced or metastatic urothelial cancer.

The antibody-drug conjugate sacituzumab govitecan demonstrated an overall response rate of 31% in heavily pretreated patients with metastatic urothelial cancer.

Arjun Balar, MD, discusses the treatment considerations he makes when treating patients with urothelial carcinoma, the role of PD-L1 tumor expression and immune checkpoint inhibitors, and the potential for new immunotherapy agents in this space.

As immunotherapies become a greater part of the treatment paradigm of various cancers, researchers are spending more time developing ways to determine which patients will respond better to immunotherapy. Mutational load is one such biomarker that appears to have an impact on response to immunotherapy, particularly for checkpoint inhibitors.

Immunotherapy treatments for several tumor types has been developing steadily for years. However, the options for patients with bladder cancer have been limited until quite recently.

Robert Huddart, professor, The Institute of Cancer Research, discusses the HYBRID trial which assessed&nbsp;hypofractionated bladder radiotherapy with or without image guided adaptive planning in elderly patients with bladder cancer.

The combination of the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.

Andrea Apolo, MD, discusses promising early data demonstrating the activity and safety of cabozantinib and nivolumab, with or without ipilimumab, in bladder cancer and other advanced genitourinary cancers.<br /> &nbsp;